TP53 and breast carcinoma: Another clinical trial targeting P53 mutations in a patient with breast cancer showed relapse 6 months after TCR-T cell therapy, with tumor cells expressing intact P53 and presenting LOH of chromosome 6 containing the HLA-A*02:01 locus (34).